Cargando…
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
Autores principales: | Farfan-Portet, María-Isabel, Gerkens, Sophie, Lepage-Nefkens, Isabelle, Vinck, Irmgard, Hulstaert, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950601/ https://www.ncbi.nlm.nih.gov/pubmed/24271016 http://dx.doi.org/10.1007/s10198-013-0538-4 |
Ejemplares similares
-
Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021) -
The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea
por: Kim, Woohyeon, et al.
Publicado: (2021) -
Expected Impact of Biosimilars on the Pharmaceutical Companies
por: Golshani, Shiva, et al.
Publicado: (2021) -
Economic-Environmental Law Guarantee of the Green and Sustainable Development: Role of Health Expenditure and Innovation
por: Yang, Lin
Publicado: (2022) -
Early modelling of the effects and healthcare costs of the Dutch citizen-rescuer system for out-of-hospital cardiac arrests
por: Ahmed, Anam, et al.
Publicado: (2023)